Similar articles

• Analysis of cytotoxicities of platinum compounds.

  Goodisman J, Hagrman D, Tacka KA, Souid AK. Goodisman J, et al. Cancer Chemother Pharmacol. 2006 Jan;57(2):257-67. doi: 10.1007/s00280-005-0041-4. Epub 2005 Jul 19. Cancer Chemother Pharmacol. 2006. PMID: 16028101
• Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.

  Samimi G, Kishimoto S, Manorek G, Breaux JK, Howell SB. Samimi G, et al. Cancer Chemother Pharmacol. 2007 Feb;59(3):301-12. doi: 10.1007/s00280-006-0271-0. Epub 2006 Jun 13. Cancer Chemother Pharmacol. 2007. PMID: 16770583
• [Cross resistance of a new platinum analogue, ACT-078, to CDDP and CBDCA].

  Misawa T, Higashide K, Konda C, Maeda O, Hasegawa N, Kikkawa F, Tomoda Y. Misawa T, et al. Gan To Kagaku Ryoho. 1995 Mar;22(4):569-71. Gan To Kagaku Ryoho. 1995. PMID: 7887652 Japanese. No abstract available.
• [Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of cancer cells, interactions with ionizing radiation, specificity of carboplatin].

  Rixe O. Rixe O. Bull Cancer. 2000 Aug;87 Spec No:7-15. Bull Cancer. 2000. PMID: 11082717 Review. French.
• DNA adducts of cisplatin, transplatin and platinum-intercalating drugs.

  Leng M, Brabec V. Leng M, et al. IARC Sci Publ. 1994;(125):339-48. IARC Sci Publ. 1994. PMID: 7806323 Review. No abstract available.